Compare CORT & WYNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | WYNN |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.1B |
| IPO Year | 2001 | 2002 |
| Metric | CORT | WYNN |
|---|---|---|
| Price | $121.38 | $75.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 21 |
| Target Price | ★ $141.00 | $130.96 |
| AVG Volume (30 Days) | 872.9K | ★ 2.1M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 1.33% |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.09 | ★ 2.36 |
| Revenue | $761,407,000.00 | ★ $6,717,660,000.00 |
| Revenue This Year | $50.53 | $4.76 |
| Revenue Next Year | $48.75 | $3.53 |
| P/E Ratio | $1,317.11 | ★ $31.90 |
| Revenue Growth | ★ 12.79 | 10.67 |
| 52 Week Low | $28.66 | $73.98 |
| 52 Week High | $126.38 | $134.72 |
| Indicator | CORT | WYNN |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 24.48 |
| Support Level | $108.33 | N/A |
| Resistance Level | $123.01 | $107.47 |
| Average True Range (ATR) | 5.11 | 2.42 |
| MACD | 0.39 | -0.00 |
| Stochastic Oscillator | 83.38 | 10.69 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, and Encore Boston Harbor in Massachusetts opened June 2019. We expect the company to continue to build nongaming rooms and attractions in Macao over the next few years, including a new 432-suite tower adjacent to its Palace resort opening in 2029. We model Wynn's managed integrated resort in the United Arab Emirates to open in 2027. The company received 49% and 51% of its 2025 prepandemic EBITDA from Macao and the US, respectively.